Investors pretty much knew what was coming with Illumina's (NASDAQ: ILMN) second-quarter results. The genomic sequencing company gave a sneak peek of those results more than two weeks ago, causing Illumina's share price to plunge.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,